Off-Label Fortified Antibiotic Therapy as a Standard Regimen for Infective Ophthalmic Pathologies and Real-Time Challenges

Abstract

Over time fortified antibiotics have become the therapy of choice for sight-threatening infective ocular pathologies as
compared to commercially available low-concentration antibiotics. However, there are multiple challenges to their use. These
include preparation under inadequate clinical settings with improperly trained staff, non-availability of designated vehicle
systems and storing medicine at extremes of temperatures - facilities for which are not available everywhere. Furthermore,
cost of these fortified antibiotics, poor patient compliance and an increased risk of infection question their main stream use.
Lastly, an ever-growing problem of the rise of "superbugs" as a result of the injudicious use of these antibiotics along with
unnecessary drug waste which contributes to climate change raises question regarding their long-term viability and necessity
for treating sight-threatening ocular pathologies